Atea Pharmaceuticals Inc
NASDAQ:AVIR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Atea Pharmaceuticals Inc
NASDAQ:AVIR
|
US |
|
TransAlta Corp
TSX:TA
|
CA |
|
S
|
SandRidge Energy Inc
SWB:SA2D
|
US |
|
American Eagle Outfitters Inc
NYSE:AEO
|
US |
|
InPlay Oil Corp
TSX:IPO
|
CA |
|
Visa Inc
NYSE:V
|
US |
|
Vivoryon Therapeutics NV
AEX:VVY
|
DE |
|
FirstGroup PLC
LSE:FGP
|
UK |
|
H
|
Halma PLC
DUS:H11
|
UK |
|
C
|
Chromocell Therapeutics Corp
AMEX:CHRO
|
US |
|
SSAB AB
OTC:SSABF
|
SE |
|
C
|
Canada One Mining Corp
XTSX:CONE
|
CA |
|
MFA Financial Inc
F:M4ZA
|
US |
|
S
|
Sharc International Systems Inc
CNSX:SHRC
|
CA |
|
Fine Organic Industries Ltd
NSE:FINEORG
|
IN |
|
Synectics PLC
F:RNR
|
UK |
|
D
|
Deutsche Boerse AG
OTC:DBOEF
|
DE |
|
Fope SpA
MIL:FPE
|
IT |
|
F
|
Fosterville South Exploration Ltd
F:4TU0
|
CA |
|
Boyd Group Services Inc
TSX:BYD
|
CA |
|
Mold-Tek Technologies Ltd
NSE:MOLDTECH
|
IN |
|
T
|
Telefonica SA
OTC:TEFOF
|
ES |
Wall St Price Targets
AVIR Price Targets Summary
Atea Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
AVIR is 8.16 USD with a low forecast of 6.06 USD and a high forecast of 10.5 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is AVIR's stock price target?
Price Target
8.16
USD
According to Wall Street analysts, the average 1-year price target for
AVIR is 8.16 USD with a low forecast of 6.06 USD and a high forecast of 10.5 USD.